How to Trade QNT (Quantinuum) on Hyperliquid

What Quantinuum Actually Is

Quantinuum is the quantum computing company formed from the 2021 merger of Honeywell Quantum Solutions and Cambridge Quantum, and it is one of the few standalone players building the full stack — hardware, software, and applications — rather than just an algorithms layer. Its bet is on trapped-ion machines, where individual atoms held in electromagnetic fields serve as qubits. The advantage of that architecture is fidelity: trapped ions tend to hold their quantum state cleanly and connect to one another flexibly, which matters more than raw qubit count for running real circuits.

That thesis got its proof point in November 2025, when Quantinuum commercially launched Helios, which it bills as the most accurate general-purpose quantum computer available. Helios shipped with paying enterprise customers already on it — Amgen, BMW Group, JPMorgan Chase, and SoftBank — working on problems from drug biologics to financial analytics. The company also markets a "GenQAI" angle, pairing quantum hardware with generative AI workloads, which is the kind of narrative that travels well in a market that rewards both themes at once.

The target customers are not retail. Quantinuum sells access through its cloud and on-premise deployments to pharma, finance, materials, and government labs. That positions QNT as a pure-play proxy for whether enterprise-grade quantum computing turns into a real commercial business this decade — not a someday science project.

The IPO Is the Whole Trade

What makes QNT live right now is timing. In May 2026 Quantinuum filed an S-1 for a Nasdaq listing under ticker QNT, offering roughly 21 million shares at $45 to $50 each to raise up to $1.05 billion at a fully diluted valuation near $12.7 billion, with J.P. Morgan and Morgan Stanley leading. It is the first traditional IPO from a full-stack quantum company, and pricing is expected on or about June 3–4.

The numbers underneath that valuation are the tension. Quantinuum reported 2025 revenue of $30.9 million and a net loss of $192.6 million, up from $23 million in revenue and a $144.1 million loss the year before. A ~$12.7 billion valuation on ~$31 million of revenue is a multiple that only makes sense as a bet on the trajectory, not the present. The S-1 also flags that a single customer, RIKEN, accounted for around 60% of 2025 revenue — real concentration risk for anyone underwriting the growth story.

There is also a policy tailwind worth naming: Quantinuum has a nonbinding letter of intent for up to $100 million from a Commerce Department package meant to back U.S. quantum firms, with the government taking a minority equity stake in exchange. That, plus Honeywell's continued backing — including a $600 million raise at a $10 billion pre-money valuation in September 2025 — is the bull case in one paragraph: scarce technology, deep-pocketed sponsor, government interest. The bear case is the income statement.

How the HIP-3 Perp Tracks a Pre-IPO Name

QNT on Hyperliquid is a HIP-3 perpetual that references the *market-implied* price per share of Quantinuum Class A stock — not an exchange print, because the stock has not started trading yet. That is the unusual part: you are trading a forward expectation of where the IPO lands and re-rates, settled through a perp rather than through a brokerage allocation you almost certainly could not get.

The contract trades with up to 5x leverage, lower than the headline leverage on liquid crypto majors, which is appropriate — a pre-IPO equity proxy is gappy and headline-driven, and modest leverage limits is the venue acknowledging that. The number traders should sit with is the spread between the perp and the deal: the perp has changed hands around $98.55, while the announced IPO range is $45 to $50. The market is pricing this name at roughly double the midpoint of what the underwriters set. That gap can be read two ways — strong pre-IPO demand that the bankers underpriced, or a perp that has run ahead of the print and has room to compress when real shares hit the tape. Either way, the listing event is a discrete catalyst, and discrete catalysts on a leveraged, thin instrument cut both directions fast.

Key Trading Considerations

Treat QNT as an event trade wrapped in a story stock, and size accordingly.

• The June listing is a binary-ish catalyst. Once shares actually trade on Nasdaq, the basis between the perp and the live stock can move violently as the market reconciles the ~$98.55 perp price with the $45–$50 offering range. Expect volatility into and out of the print.
• The fundamentals are venture-stage. ~$31 million in revenue against a $192.6 million loss and 60% customer concentration in RIKEN means this is priced on narrative and TAM, not cash flows. Quantum-computing timelines for fault-tolerant systems still run years out; sentiment toward the whole sector can swing the tape more than anything company-specific.
• Honeywell still controls the cap table. Founders retain roughly 82% of equity post-IPO, with Honeywell holding about 49.1% of the voting power. Float will be thin, which amplifies moves in both the equity and, indirectly, the perp.
• Liquidity is shallow. Recent 24h perp volume is around $8.18 million. That is enough to trade but not enough to move size without slippage, so respect the book and keep leverage well under the 5x cap into the listing.